LymphedemaV1, Main, Exploration, bibRecord, 002131

Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination

Identifieur interne : 002131 ( Main/Exploration ); précédent : 002130; suivant : 002132

Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination

Auteurs : Neal D. E. Alexander

Source :

Transactions of the Royal Society of Tropical Medicine and Hygiene [ 0035-9203 ] ; 2015.

RBID : PMC:4321021

Descripteurs français

KwdFr :
- Diéthylcarbamazine (administration et posologie), Filaricides (administration et posologie), Filariose lymphatique (), Humains, Mise en oeuvre des programmes de santé (organisation et administration), Éradication de maladie.
MESH :
- administration et posologie : Diéthylcarbamazine, Filaricides.
- organisation et administration : Mise en oeuvre des programmes de santé.
- Filariose lymphatique, Humains, Éradication de maladie.

English descriptors

KwdEn :
- Diethylcarbamazine (administration & dosage), Disease Eradication, Elephantiasis, Filarial (prevention & control), Filaricides (administration & dosage), Health Plan Implementation (organization & administration), Humans.
MESH :
- chemical , administration & dosage : Diethylcarbamazine, Filaricides.
- organization & administration : Health Plan Implementation.
- prevention & control : Elephantiasis, Filarial.
- Disease Eradication, Humans.

Abstract

Lymphatic filariasis has been targeted for elimination by 2020, and a threshold of 65% coverage of mass drug administration (MDA) has been adopted by the Global Programme to Eliminate Lymphatic Filariasis (GPELF). A recent review by Babu and Babu of 36 studies of MDA for lymphatic filariasis in India found that coverage, defined as receipt of tablets, ranged from 48.8 to 98.8%, while compliance, defined as actual ingestion of tablets, was 22% lower on average. Moreover, the denominator for these coverage figures is the eligible, rather than total, population. By contrast, the 65% threshold, in the original modelling study, refers to ingestion of tablets in the total population. This corresponds to GPELF's use of ‘epidemiological drug coverage’ as a trigger for the Transmission Assessment Surveys (TAS), which indicate whether to proceed to post-MDA surveillance. The existence of less strict definitions of ‘coverage’ should not lead to premature TAS that could impair MDA's sustainability.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321021

DOI: 10.1093/trstmh/tru204
PubMed: 25575555
PubMed Central: 4321021

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination</title>
<author><name sortKey="Alexander, Neal D E" sort="Alexander, Neal D E" uniqKey="Alexander N" first="Neal D. E." last="Alexander">Neal D. E. Alexander</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25575555</idno>
<idno type="pmc">4321021</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321021</idno>
<idno type="RBID">PMC:4321021</idno>
<idno type="doi">10.1093/trstmh/tru204</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">004651</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004651</idno>
<idno type="wicri:Area/Pmc/Curation">004650</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">004650</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001497</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001497</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001097</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001097</idno>
<idno type="wicri:Area/PubMed/Curation">001097</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001097</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001097</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001097</idno>
<idno type="wicri:Area/Ncbi/Merge">006F15</idno>
<idno type="wicri:Area/Ncbi/Curation">006F15</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">006F15</idno>
<idno type="wicri:doubleKey">0035-9203:2015:Alexander N:are:we:nearly</idno>
<idno type="wicri:Area/Main/Merge">002134</idno>
<idno type="wicri:Area/Main/Curation">002131</idno>
<idno type="wicri:Area/Main/Exploration">002131</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination</title>
<author><name sortKey="Alexander, Neal D E" sort="Alexander, Neal D E" uniqKey="Alexander N" first="Neal D. E." last="Alexander">Neal D. E. Alexander</name>
</author>
</analytic>
<series><title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title>
<idno type="ISSN">0035-9203</idno>
<idno type="eISSN">1878-3503</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Diethylcarbamazine (administration & dosage)</term>
<term>Disease Eradication</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Filaricides (administration & dosage)</term>
<term>Health Plan Implementation (organization & administration)</term>
<term>Humans</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Diéthylcarbamazine (administration et posologie)</term>
<term>Filaricides (administration et posologie)</term>
<term>Filariose lymphatique ()</term>
<term>Humains</term>
<term>Mise en oeuvre des programmes de santé (organisation et administration)</term>
<term>Éradication de maladie</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diethylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diéthylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Mise en oeuvre des programmes de santé</term>
</keywords>
<keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Health Plan Implementation</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Disease Eradication</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Filariose lymphatique</term>
<term>Humains</term>
<term>Éradication de maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Lymphatic filariasis has been targeted for elimination by 2020, and a threshold of 65% coverage of mass drug administration (MDA) has been adopted by the Global Programme to Eliminate Lymphatic Filariasis (GPELF). A recent review by Babu and Babu of 36 studies of MDA for lymphatic filariasis in India found that coverage, defined as receipt of tablets, ranged from 48.8 to 98.8%, while compliance, defined as actual ingestion of tablets, was 22% lower on average. Moreover, the denominator for these coverage figures is the eligible, rather than total, population. By contrast, the 65% threshold, in the original modelling study, refers to ingestion of tablets in the total population. This corresponds to GPELF's use of ‘epidemiological drug coverage’ as a trigger for the Transmission Assessment Surveys (TAS), which indicate whether to proceed to post-MDA surveillance. The existence of less strict definitions of ‘coverage’ should not lead to premature TAS that could impair MDA's sustainability.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Stolk, Wa" uniqKey="Stolk W">WA Stolk</name>
</author>
<author><name sortKey="Swaminathan, S" uniqKey="Swaminathan S">S Swaminathan</name>
</author>
<author><name sortKey="Van Oortmarssen, Gj" uniqKey="Van Oortmarssen G">GJ van Oortmarssen</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Babu, Bv" uniqKey="Babu B">BV Babu</name>
</author>
<author><name sortKey="Babu, Gr" uniqKey="Babu G">GR Babu</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Krentel, A" uniqKey="Krentel A">A Krentel</name>
</author>
<author><name sortKey="Fischer, Pu" uniqKey="Fischer P">PU Fischer</name>
</author>
<author><name sortKey="Weil, Gj" uniqKey="Weil G">GJ Weil</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Al Awadi, Ar" uniqKey="Al Awadi A">AR Al-Awadi</name>
</author>
<author><name sortKey="Al Kuhlani, A" uniqKey="Al Kuhlani A">A Al-Kuhlani</name>
</author>
<author><name sortKey="Breman, Jg" uniqKey="Breman J">JG Breman</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Richards, Fo" uniqKey="Richards F">FO Richards</name>
</author>
<author><name sortKey="Eigege, A" uniqKey="Eigege A">A Eigege</name>
</author>
<author><name sortKey="Miri, Es" uniqKey="Miri E">ES Miri</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Swaminathan, S" uniqKey="Swaminathan S">S Swaminathan</name>
</author>
<author><name sortKey="Perumal, V" uniqKey="Perumal V">V Perumal</name>
</author>
<author><name sortKey="Adinarayanan, S" uniqKey="Adinarayanan S">S Adinarayanan</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Alexander, Neal D E" sort="Alexander, Neal D E" uniqKey="Alexander N" first="Neal D. E." last="Alexander">Neal D. E. Alexander</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002131 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002131 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:4321021
   |texte=   Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25575555" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

Serveur d'exploration sur le lymphœdème

Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination

Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.